Two NOFOs, PAR-23-279 (R01, clinical trial optional) and PAR-23-280 (R21, clinical trial not allowed), “Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics”, call for scientists to submit projects that address mechanisms by which incretin mimetics, specifically glucagon-like peptide (GLP)-1 or dual GLP-1/glucose-dependent insulinotropic polypepide (GIP)-1 receptor agonists (RAs), impact cancer risk. Here, GCG is linked to cancer.